

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSING IN
US PHASE III CLINICAL TRIAL OF PROXALUTAMIDE FOR THE
TREATMENT OF HOSPITALIZED COVID-19 PATIENTS**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Kintor Pharma**”) to update its shareholders and potential investors on the latest business advancement of the Group.

References are made to the announcements of the Company dated 18 May 2021, 1 September 2021 and 26 September 2021, respectively (the “**Announcements**”). Unless the context requires otherwise, the capitalised terms used in this announcement shall have the same meanings as defined in the Announcements.

The Board is pleased to announce that, as at 1 October 2021, the phase III clinical trial of proxalutamide for the treatment of hospitalized COVID-19 patients has enrolled and dosed its first patient in the United States of America (the “**US Phase III Clinical Trial**”).

As part of Kintor Pharma’s plan to conduct pivotal multi-regional clinical trials of proxalutamide for the treatment of hospitalized COVID-19 patients in more than ten countries and regions, the US Phase III Clinical Trial (NCT05009732) is a randomized, double-blind, placebo-controlled, multi-regional pivotal trial, designed to evaluate the efficacy and safety of proxalutamide in hospitalized COVID-19 patients. The primary endpoint for the trial is the time to sustained recovery evaluated by Day 30. The secondary endpoint of the trial is 30-day mortality. This pivotal study has been approved by the US FDA, the NMPA, the Philippines FDA and ANVISA, and is seeking for approval by more regulatory agencies in Europe and Asia.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Proxalutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 4 October 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*